“What is truly important for us is to take out the customercentricity and the innovativeness of the two units and with all the synergies bring that to the next level in the market and to grow even stronger in the future,” Ceranski relayed.
‘We create chemistry’
While the Cognis input saw the new Nutrition unit double its revenue to about €2bn in 2011 – it is a small part of BASF’s €73.5bn income last year. But Ceranski said the division was central to the wider group’s just-launched, 10-year ‘we create chemistry’ strategy.
“Food and nutrition is at the core of the BASF group so the business of human nutrition is also at the core so that means that BASF wants to invest in research, development applications but also in people to make sure we are close to our customers and offer products that are innovative…”
Growth may come both organically and via other acquisitions, he said, noting increased growth rates in emerging markets.
BASF had, “walked the talk” he said when it came to nutrition investment, with the recent purchase of Scottish high-dose omega-3 supplier Equateq.
“We were looking for some time to go into the premium segment of omega-3s and we discovered Equateq…”
Michael Ceranski is the senior vice president, global business unit at BASF Human Nutrition and a man who is instrumental in determining the fate of BASF’s new nutrition activities. He took some time to speak with us at Vitafoods Europe last week.
